




Suzetrigine Alleviates Severe Chronic Angina for a Patient during the Perioperative Period

Jordan Noble MD, Alastair Moody MD, Emilee Borgmeier MD

Department of Anesthesiology Perioperative and Pain Medicine, University of Utah Health Hospital, Salt Lake City, UT



Introduction:

- Suzetrigine is a novel sodium channel 1.8 inhibitor that is marketed as a drug that improves patient pain scores in the acute setting¹⁻³
- While initial studies are promising, overall data is limited until more studies are published on demonstrated benefit⁴
- I present the case report of Suzetrigine incidentally providing relief from chronic, refractory angina when given in the perioperative period

Materials and Methods:

- Information contained in this case report is devoid of identifiable patient information and is therefore exempt from IRB review requirements per University of Utah policy
- Informed consent was obtained from the patient for this presentation and only pertinent information related to the patient’s medical course was included

Case Report:

- A 58-year-old male on opioids for severe chronic angina presented for a cholecystectomy
- History of multiple procedures for angina without relief including coronary stenting, CABGs, balloon angioplasties, bilateral sympathectomies, and a transmyocardial revascularization
- Current medications include a Fentanyl 25 mcg/hr patch, Oxycodone 10 mg TID, Lyrica 75 mg BID, and Ranolazine 1000 mg BID
- Preoperative meds: Suzetrigine 100 mg, Lyrica 75 mg, and Acetaminophen 975 mg
- Intraoperative meds: Fentanyl 150 mcg, Ketamine 20 mg, and Methadone 20 mg
- Given his cardiac history, NSAIDs were excluded, and the patient was admitted for observation overnight
- Post-operative meds: Acetaminophen, Suzetrigine, and home medications
- Notably, on POD1 the patient reported relief from his angina for the first time in decades. He had previously tried Acetaminophen, Ketamine and Methadone without benefit, and he attributed his angina resolution to Suzetrigine

Case Report Cont.

- He discharged with Suzetrigine for fourteen days but was unable to continue the medication as it is not yet approved for chronic use
- His angina has returned, and he is waiting with his palliative care provider for more studies recommending Suzetrigine for chronic pain management

Discussion:

- This case report demonstrates the benefit of using a multimodal regimen to target the complexity of nociception
- This patient has severe angina and requires opioids to function. Medications like Suzetrigine that permit providers to reduce opioid consumption deserve consideration³⁻⁴
- While the mechanism of how Suzetrigine relieved angina is unknown, its benefit remains profound⁵
- This case report adds to the potential establishment of Suzetrigine as a standard medication for both acute and chronic pain management.

Resources:
1 Jones J, Correll DJ, Lechner SM, Jazic I, Miao X, Shaw D, Simard C, Osteen JD, Hare B, Beaton A, Bertoch T, Buvanendran A, Habib AS, Pizzi LJ, Pollak RA, Weiner SG, Bozic C, Negulescu P, White PF; VX21-548-101 and VX21-548-102 Trial Groups. Selective Inhibition of Na_v1.8 with VX-548 for Acute Pain. N Engl J Med. 2023 Aug 3;389(5):393-405. doi: 10.1056/NEJMoa2209870. PMID: 37530822. 2. Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21. PMID: 40117446; PMCID: PMC12061372. 3. < Osteen JD, Immani S, Tapley TL, Indersmitten T, Hurst NW, Healey T, Aertgeerts K, Negulescu PA, Lechner SM. Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Na_v1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain. Pain Ther. 2025 Apr;14(2):655-674. doi: 10.1007/s40122-024-00697-0. Epub 2025 Jan 8. PMID: 39775738; PMCID: PMC11914629 4. < Karri J, D'Souza RS, Cohen SP. Between promise and peril: role of suzetrigine as a non-opioid analgesic. BMJ Med. 2025 Mar 25;4(1):e001431. doi: 10.1136/bmjmed-2025-001431. PMID: 40151204; PMCID: PMC11948347. 5. Rathmell JP, Clark JD, Eisenach JC. Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain. Anesthesiology. 2025 Jun 1;142(6):989-991. doi: 10.1097/ALN.0000000000005465. Epub 2025 May 13. PMID: 40358331